Hydronephrosis Market Overview
The Hydronephrosis Market report analyzes the global market size, shares, recent trends, competitive intelligence, and future market outlook. Hydronephrosis is a condition characterized by the swelling of the kidneys due to the buildup of urine caused by an obstruction in the urinary tract. The market is driven by the increasing prevalence of urinary tract disorders, the growing awareness about early diagnosis and treatment, and advancements in diagnostic techniques. In America, the Hydronephrosis Market is experiencing substantial growth. Key players in the market include Siemens Healthineers AG, Boston Scientific Corporation, Stryker Corporation, and other prominent players.
A blockage causes hydronephrosis in the tube that links the kidney to the bladder (ureter). A kidney stone, an infection, an enlarged prostate, a blood clot, or a tumor is a possible reason. Symptoms include soreness in the side, abdomen, or groin and difficulties urinating. If there is an infection, medications are prescribed. The urine may need to be evacuated from the bladder or kidney in severe cases.
As per DataM Intelligence, the Hydronephrosis Market study analysis offers an in-depth outlook on the market containing quantitative and qualitative data. It gives an outlook and forecast of the global market based on market segmentation. It also provides global Hydronephrosis Market size, and growth, along with the latest trends, opportunities, and forecast till 2029 for the global market with esteem to major countries such as the United States, Canada, Brazil, Germany, Italy, Spain, United Kingdom, Russia, European countries, United Arab Emirates, Saudi Arabia, South Africa, Japan, China, India, South Korea, Australia, and rest of the countries over the globe.
Among all regions, the North American region is expected to hold the largest share of the global market over the forecast period. Hydronephrosis Market in the United States and Canada produces the utmost share. Whereas the European Hydronephrosis Market is projected to continue its presence globally from 2023 to 2030.
Market Scope and Summary
| Metrics | Details |
| Market CAGR | 9.5% |
| Segments Covered | By Type, By Diagnosis, By Treatment, By Distribution Channel, By End-User, and By Region |
| Report Insights Covered | Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights. |
| Fastest Growing Region | Asia Pacific |
| Largest Market Share | North America |
For more insights - Download the Sample
Market Dynamics and Trends
Advancement in the devices for the treatment of pre-operative hydronephrosis is expected to drive market growth.
Ureteral stenting significantly resolves pre-operative hydronephrosis after URS lithotripsy in patients with ureteral stones. Ureteral stent placement is the preferred method for the treatment of pre-operative hydronephrosis. Moreover, Prenatal ultrasonography (US) was widely used, allowing clinicians to discover urinary tract problems considerably earlier and more frequently than in the past. Thus, the market is expected to drive in the forecast period from the above statements.
Restraint:
Unfavorable reimbursement policies, lack of awareness about the diseases and treatment, shortage of skilled professionals, and availability of alternative procedures are some factors the market is expected to get hampered in the forecast period.
COVID-19 Impact on Hydronephrosis Market Growth
The COVID-19 pandemic has moderately impacted healthcare systems and the market. People suffering from severe cases of COVID-19 will show signs of kidney damage, even those who had no underlying kidney problems before they were infected with the coronavirus. Signs of kidney problems in patients with COVID-19 include high protein levels or blood in the urine and abnormal blood work. Moreover, with the emergence of COVID-19 and the high prevalence of preoperative hydronephrosis in upper urinary tract urothelial carcinoma (UTUC) patients, this condition appears to have gotten more pronounced due to the certainty of waiting time for surgery. Additionally, the pandemic interrupts the supply chain. Many companies will vary to other geographic regions to ensure that products remain available and protect their supply chain. Thus, from the above statements, the market got affected, and it is expected to gain traction quickly with the resumption of economic activities.
Market Segment and Shares
The surgery segment is expected to hold the largest market share in the hydronephrosis market
The surgery segment is expected to dominate in 2021. The segment's growth is beneficial because pyeloplasty is the most common surgical treatment for hydronephrosis. It is used to treat the most frequent obstruction, where the kidney meets the ureter (ureteropelvic junction blockage). It reconnects the healthy segment of the tube from the kidney to the bladder (ureter) with the kidney's drainage system after removing the constricted or obstructed portion. Moreover, the surgeon may perform pyeloplasty in traditional or open incision methods, robot-assisted pyeloplasty, and laparoscopic pyeloplasty. Thus, the market segment is expected to hold the largest market share in the forecast period from the above statements.
Market Geographical Analysis
North America region holds the largest market share in the global hydronephrosis market
In 2021, North America accounted for the highest revenue share. The increasing prevalence of hydronephrosis, the rising geriatric population, increased spending on research and development, high health expenditures, and the launch of technologically advanced products in the region are factors the market is expected to boost in the forecast period. For instance, the prevalence ranges from 0.15 percent to 0.67 percent in the general population. 1 case per 100 to 200 fetuses is the frequency determined by prenatal ultrasonography. The ratio of males to females is 2:1. Bilateral instances account for 10% to 20% of all cases.
Moreover, hydronephrosis is a critical factor in determining rapid diagnosis, the best therapeutic method, and patient follow-up. To the severity of hydronephrosis in babies, various hydronephrosis grading methods have been devised, including AP diameter, SFU, radiography, UTD, and Onen. Thus, the North American region is expected to hold the largest market share in the forecast period from the above statements.
Companies and Competitive Landscape
Major key players in the hydronephrosis market are Lupin Pharmaceuticals, Inc., Pfizer Inc., Bayer HealthCare Pharmaceuticals Inc., GlaxoSmithKline plc., Mallinckrodt Pharmaceuticals, Johnson & Johnson Consumer Inc., Roche Laboratories Inc., Teva Pharmaceuticals USA, Inc.
Pfizer Inc.:
Overview:
Pfizer Inc. is an American multinational pharmaceutical company that offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. It has a portfolio of over 150 products across 15 therapeutic areas. The company develops and produces medicines and vaccines for a wide range of medical disciplines, including immunology, oncology, cardiology, endocrinology, and neurology.
Product Portfolio:
Ciprofloxacin: Ciprofloxacin is an important, widely used antibiotic. It is classified into the fluoroquinolone group and is widely used to treat infection of the gastrointestinal tract, respiratory tract, and genitourinary tract.
